Protected CHIP PCI in Severe LV Dysfunction: An Illustrative Case Highlighting Patient Selection, Procedural Planning, Execution and Device Management

Abstract Ischemic left ventricle dysfunction (ILVD) is the leading cause of heart failure and is commonly encountered in cardiac catheterisation laboratories. Patients presenting with ILVD are typically older and often have complex coronary anatomy, making revascularisation challenging. Although coronary artery bypass grafting (CABG) improves long-term survival in patients with ILVD compared to medical therapy, the benefit emerges only after a decade and appears limited to younger patients, leaving many older, frail, or comorbid individuals at untenable risk. Such patients are frequently considered for complex high-risk indicated percutaneous coronary intervention (CHIP), where the primary determinant of procedural risk is intraprocedural haemodynamic instability due to limited ventricular reserve and anticipated prolonged ischemia. Registry data underscores the heightened risk in patients with multiple CHIP features, including ejection fraction (EF) ≤30%, left main or multivessel percutaneous coronary intervention (PCI), and extensive calcification. Here, temporary mechanical circulatory support (tMCS) has emerged as a strategy to mitigate haemodynamic compromise during CHIP procedures. Although trial data has demonstrated no early benefit with the intra-aortic balloon pump (IABP), long-term follow-up suggests improved survival. Alternatively, micro-axial flow pumps (mAFP), such as Impella™, can offer robust haemodyanic support and a reduction in late major adverse events. Although results from the ongoing randomized clinical trials with Impella are pending, careful Heart Team evaluation and procedural planning remain essential to ensure the best possible patient outcomes. Here, we illustrate a structured approach to Impella-supported CHIP in an elderly patient with the presence of ILVD, severely impaired ventricular reserve, and heavily calcified multivessel disease.

Authors

Institutions

Publication Details

Journal
European Heart Journal Supplements
Published
2026-02-16
DOI
https://doi.org/10.1093/eurheartjsupp/suag008
Primary Topic
Mechanical Circulatory Support Devices
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Protected CHIP PCI in Severe LV Dysfunction: An Illustrative Case Highlighting Patient Selection, Procedural Planning, Execution and Device Management

Saad Ezad, V Panoulas, M Monteagudo-Vela, M Alkhalil et al.
European Heart Journal Supplements
Mechanical Circulatory Support Devices
article

Protected CHIP PCI in Severe LV Dysfunction: An Illustrative Case Highlighting Patient Selection, Procedural Planning, Execution and Device Management

Saad Ezad, V Panoulas, M Monteagudo-Vela, M Alkhalil, Christophe Vandenbriele
article en

Abstract

Abstract Ischemic left ventricle dysfunction (ILVD) is the leading cause of heart failure and is commonly encountered in cardiac catheterisation laboratories. Patients presenting with ILVD are typically older and often have complex coronary anatomy, making revascularisation challenging. Although coronary artery bypass grafting (CABG) improves long-term survival in patients with ILVD compared to medical therapy, the benefit emerges only after a decade and appears limited to younger patients, leaving many older, frail, or comorbid individuals at untenable risk. Such patients are frequently considered for complex high-risk indicated percutaneous coronary intervention (CHIP), where the primary determinant of procedural risk is intraprocedural haemodynamic instability due to limited ventricular reserve and anticipated prolonged ischemia. Registry data underscores the heightened risk in patients with multiple CHIP features, including ejection fraction (EF) ≤30%, left main or multivessel percutaneous coronary intervention (PCI), and extensive calcification. Here, temporary mechanical circulatory support (tMCS) has emerged as a strategy to mitigate haemodynamic compromise during CHIP procedures. Although trial data has demonstrated no early benefit with the intra-aortic balloon pump (IABP), long-term follow-up suggests improved survival. Alternatively, micro-axial flow pumps (mAFP), such as Impella™, can offer robust haemodyanic support and a reduction in late major adverse events. Although results from the ongoing randomized clinical trials with Impella are pending, careful Heart Team evaluation and procedural planning remain essential to ensure the best possible patient outcomes. Here, we illustrate a structured approach to Impella-supported CHIP in an elderly patient with the presence of ILVD, severely impaired ventricular reserve, and heavily calcified multivessel disease.

European Heart Journal Supplements
Guy's and St Thomas' NHS Foundation Trust (GB), Royal Bournemouth Hospital (GB), Freeman Hospital (GB), Harefield Hospital (GB), British Heart Foundation (GB), Lung Institute (US), Onze Lieve Vrouwziekenhuis Hospital (BE), Klinik und Poliklinik für Psychotherapie und Psychosomatik (DE), Imperial College London (GB), Technische Universität Dresden (DE), Newcastle University (GB)
Good health and well-being
Openalex Percentile: Top 52%
Mechanical Circulatory Support Devices
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.